The Use of Recombinant Human Erythropoietin in the Treatment of the Anemia of Chronic Disorders
Common infectious diseases as well as numerous noninfectious disorders such as rheumatoid arthritis, Hodgkin’s disease, and metastatic carcinomas are associated with a similar type of anemia. As defined by Cartwright in his classic 1966 review : “The anaemia is usually mild in the degree and not progressive in severity and is characterized by a low plasma iron, decreased total iron binding capacity, decreased saturation of transferrin with iron, decreased bone marrow sideroblasts, normal or increased reticuloendothelial iron, increased plasma copper and increased free erythrocyte protoporphyrin.” Being roughly proportional to the severity of the underlying disease, hemoglobin (Hb) concentrations usually range from 7.0 to 11.0 g/dl [5,14]. A variety of names have been proposed for this anemia, but since etiology and pathogenesis are still far from being clarified the most commonly used name is anemia of chronic disorders (ACD). ACD is thought to be a common feature in the broad spectrum of infections and inflammatory diseases . There is in the literature, however, surprisingly little in the way of controlled data about its incidence. In an analysis conducted at the Rheumatology Unit of the University Hospital of Frankfurt, we calculated an incidence of 7.3% for ACD in a population of 218 patients with various rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and mixed connective tissue disease (MCT; Fig. 1).
KeywordsRheumatoid Arthritis Systemic Lupus Erythematosus Serum Ferritin Recombinant Human Erythropoietin Mixed Connective Tissue Disease
Unable to display preview. Download preview PDF.
- 4.Birgegard G, Gudbjörnsson B, Hällgren R, Wide L (1991) Anemia of chronic inflammatory arthritides: treatment with recombinant human erythropoietin. In: Gurland HJ, Movan J. Samtleben W, Scigalla P, Wieczovek L (eds) Erythropoietin in renal and non-renal anemias. Contrib Nephrol 88: 295–303Google Scholar
- 6.Cotes, PM, Brozovic B, Mansell M, Samson DM (1980) Radioimmunoassay of erythropoietin in human serum. Exp Hematol 8: 292Google Scholar
- 8.Erslev A J (1983) Anemia of chronic disorders. In: Williams WJ, Beutler E. Erslev A J, Lichtman MA (eds) Hematology 3rd edn. McGraw-Hill, New York, pp 522–528Google Scholar
- 13.Konijn AM, Hershko C (1977) Ferritin synthesis in inflammation. I. Mechanism of impaired iron release. Br J Haematol 37: 7–16Google Scholar
- 15.Maury CPJ, Andersson LC,Teppo AM, Partanen S, en Juvon E (1988) Mechanism of anemia in rheumatoid arthritis: demonstration of raised interleukin-l-beta concentrations in anemic patients and of interleukin-1 mediated supression of normal erythropoiesis and proliferation of human erythroleucaemia ( HEL) cells in vitro. Ann Rheum Dis 47: 972–978PubMedCrossRefGoogle Scholar
- 19.Takashina, N., Kondo H, Kashiwazki S (1990) Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. Rheumatol 17: 885–887Google Scholar
- 20.Wallner, SF (1983) The anemia of chronic disorders: clinical and pathological features. In: Dunn, CDR (ed) Current concepts in erythropoiesis. Wiley, Chichester, pp 209–231Google Scholar